Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Melanoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Solid Tumors 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1PD-L1-selected Solid Tumors 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1Advanced Rare Malignant Solid Neoplasm 1

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Rare Malignant Solid Neoplasm × Tiragolumab × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡